Summary
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them.
The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.
Official Title
A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.
Keywords
Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer, B6C, integrin beta 6, ADC, antibody drug conjugate, non-small cell lung cancer, NSCLC, HNSCC, SCCHN, EC, PDAC, lung adenocarcinoma, lung squamous cell carcinoma, integrin alpha-v beta-6 receptor, ITGB6, Urinary Bladder Neoplasms, Transitional Cell Carcinoma, Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Esophageal Neoplasms, Adenocarcinoma Of Esophagus, Pancreatic Neoplasms, Adenocarcinoma of Lung